Efficacy of olanzapine long-acting injection in patients with acutely exacerbated schizophrenia: an insight from effect size comparison with historical oral data

被引：0
|
作者：
Holland C Detke
Fangyi Zhao
Michael M Witte
机构：
[1] Eli Lilly and Company,
[2] Lilly USA,undefined
[3] LLC,undefined
来源：
BMC Psychiatry | / 12卷
关键词：
Olanzapine; Long-acting injection; Pamoate; Haloperidol; Effect size; Onset; Pharmacokinetics;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] COST-EFFECTIVENESS OF OLANZAPINE LONG-ACTING INJECTION IN THE TREATMENT OF NON-ADHERENCE PATIENTS WITH SCHIZOPHRENIA IN THE UNITED STATES
    Ascher-Svanum, H.
    Furiak, N. M.
    Klein, R. W.
    Montgomery, W.
    Smolen, L. J.
    Lawson, A. H.
    Conley, R. R.
    VALUE IN HEALTH, 2009, 12 (03) : A176 - A176
  • [42] SWITCHING TO OLANZAPINE LONG-ACTING INJECTION FROM EITHER ORAL OLANZAPINE OR ANY OTHER ANTIPSYCHOTIC: COMPARATIVE POST-HOC ANALYSES
    Ciudad, Antonio
    Casillas, Marta
    Schacht, Alexander
    Anand, Ernie
    Perrin, Elena
    SCHIZOPHRENIA RESEARCH, 2012, 136 : S260 - S260
  • [43] Cost-Effectiveness of Olanzapine Long-Acting Injection in the Treatment of Non-Adherent Patients with Schizophrenia in the United States
    Ascher-Svanum, H.
    Furiak, N. M.
    Klein, R. W.
    Montgomery, W.
    Smolen, L. J.
    Lawson, A. H.
    Conley, R. R.
    JOURNAL OF MENTAL HEALTH POLICY AND ECONOMICS, 2009, 12 : S4 - S4
  • [44] Dose-associated changes in safety and efficacy parameters observed in a 24-week maintenance trial of olanzapine long-acting injection in patients with schizophrenia
    Karagianis, J.
    Guilliver, A.
    Sun, B.
    Zhao, F.
    Watson, S.
    McDonnell, D.
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2010, 13 : 223 - 223
  • [45] Dose-associated changes in safety and efficacy parameters observed in a 24-week maintenance trial of olanzapine long-acting injection in patients with schizophrenia
    Angela L Hill
    Bin Sun
    Jamie L Karagianis
    Susan B Watson
    David P McDonnell
    BMC Psychiatry, 11
  • [46] Dose-associated changes in safety and efficacy parameters observed in a 24-week maintenance trial of olanzapine long-acting injection in patients with schizophrenia
    Hill, Angela L.
    Sun, Bin
    Karagianis, Jamie L.
    Watson, Susan B.
    McDonnell, David P.
    BMC PSYCHIATRY, 2011, 11
  • [47] Clinical and functional outcomes of patients with schizophrenia treated with risperidone long-acting injection versus oral antipsychotics
    Olivares, J. M.
    Morales, A. Rodriguez
    Diels, J.
    Povey, M.
    Lam, A.
    Zhao, Z.
    EUROPEAN PSYCHIATRY, 2008, 23 : S126 - S127
  • [48] Research article Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, I: analysis of cases
    Detke, Holland C.
    McDonnell, David P.
    Brunner, Elizabeth
    Zhao, Fangyi
    Sorsaburu, Sebastian
    Stefaniak, Victoria J.
    Corya, Sara A.
    BMC PSYCHIATRY, 2010, 10
  • [49] Olanzapine Long-Acting Injection: A 24-Week, Randomized, Double-Blind Trial of Maintenance Treatment in Patients With Schizophrenia
    Kane, John M.
    Detke, Holland C.
    Naber, Dieter
    Sethuraman, Gopalan
    Lin, Daniel Y.
    Bergstrom, Richard F.
    McDonnell, David
    AMERICAN JOURNAL OF PSYCHIATRY, 2010, 167 (02): : 181 - 189
  • [50] STUDY ON TOLERABILITY AND EFFICACY OF PALIPERIDONE PALMITATE, OLANZAPINE PAMOATE AND RISPERIDONE LONG ACTING INJECTION IN A ROMANIAN SAMPLE OF PATIENTS WITH SCHIZOPHRENIA
    Enatescu, Virgil-Radu
    Dehelean, Cristina Adriana
    Nussbaum, Laura Alexandra
    Hogea, Lavinia
    Homorogan, Claudia
    Enatescu, Ileana
    Papava, Ion
    Marinescu, Ileana
    Ifteni, Petru
    Simu, Mihaela
    Catalin, Marian
    Giurgi-Oncu, Catalina
    Sirbu, Ioan-Ovidiu
    FARMACIA, 2020, 68 (02) : 242 - 249
12345